398 related articles for article (PubMed ID: 25469525)
1. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry.
Vannappagari V; Koram N; Albano J; Tilson H; Gee C
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):359-64. PubMed ID: 25469525
[TBL] [Abstract][Full Text] [Related]
2. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.
Vannappagari V; Koram N; Albano J; Tilson H; Gee C
BJOG; 2016 May; 123(6):910-6. PubMed ID: 26269220
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Floridia M; Pinnetti C; Ravizza M; Masuelli G; Personeni C; Sansone M; Degli Antoni A; Guaraldi G; Spinillo A; Tassis B; Dalzero S; Liuzzi G; Tamburrini E
J Acquir Immune Defic Syndr; 2018 May; 78(1):99-104. PubMed ID: 29406430
[TBL] [Abstract][Full Text] [Related]
4. Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis.
Tshivuila-Matala COO; Honeyman S; Nesbitt C; Kirtley S; Kennedy SH; Hemelaar J
AIDS; 2020 Sep; 34(11):1643-1656. PubMed ID: 32701581
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group
AIDS; 2019 Feb; 33(2):295-304. PubMed ID: 30562172
[TBL] [Abstract][Full Text] [Related]
6. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
7. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
[TBL] [Abstract][Full Text] [Related]
10. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
Vannappagari V; Thorne C;
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
13. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Berenguer J; Pérez-Elías MJ; Bellón JM; Knobel H; Rivas-González P; Gatell JM; Miguélez M; Hernández-Quero J; Flores J; Soriano V; Santos I; Podzamczer D; Sala M; Camba M; Resino S;
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):154-9. PubMed ID: 16394846
[TBL] [Abstract][Full Text] [Related]
17. Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children.
Bossacoma Busquets F; Sánchez E; Noguera-Julián A; Villaronga Flaqué M; Fortuny C
J Clin Pharm Ther; 2021 Aug; 46(4):867-871. PubMed ID: 33393094
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
Suzuki A; Uehara Y; Saita M; Inui A; Isonuma H; Naito T
Jpn J Infect Dis; 2016; 69(1):33-8. PubMed ID: 25971320
[TBL] [Abstract][Full Text] [Related]
19. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Michienzi SM; Schriever CA; Badowski ME
Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]